6CM
KLRS

683 Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

683 Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$260K Sell
45,000
-35,590
-44% -$316K 0.01% 212
2025
Q4 		$680K Buy
+80,590
New +$515K 0.03% 172
2024
Q1 		– Sell
-8,286
Closed -$130K – 269
2023
Q4 		$130K Buy
+8,286
New +$327K 0.01% 215

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

683 Capital Management's KLRS Position: Q1 2026 in Review

683 Capital Management reduced its Kalaris Therapeutics (KLRS) stake by 44% in Q1 2026, selling an estimated $316K and leaving 45,000 shares worth $260K. The position accounts for 0.01% of the portfolio, ranked #212.

683 Capital Management first reported a position in KLRS in Q4 2023 and has held it in 3 quarters since. The position peaked at $680K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • 683 Capital Management held 45,000 shares of Kalaris Therapeutics worth $260K as of Q1 2026.
  • 683 Capital Management sold 35,590 Kalaris Therapeutics shares in Q1 2026, an estimated $316K.
  • Kalaris Therapeutics made up 0.01% of 683 Capital Management's portfolio in Q1 2026, its #212 holding.
  • 683 Capital Management first reported a position in Kalaris Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 683 Capital Management's Kalaris Therapeutics position peaked at $680K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.